Interestingly, the combination of PIK3CA and SOX2 amplification allowed us to distinguish three different cancer risk subgroups: patients who carried amplification of both genes exhibited the highest risk of progression to laryngeal carcinoma, whereas patients with amplification of a single gene showed an intermediate risk, and the amplification-negative subgroup had the lowest cancer risk. Here, PIK3CA is linked to cancer.